Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: WAC

Gene summary for WAC

Gene summary.

Gene information	Species	Human
	Gene symbol	WAC
	Gene ID	51322
	Gene name	WW domain containing adaptor with coiled-coil
	Gene Alias	BM-016
	Cytomap	10p12.1
	Gene Type	protein-coding
	GO ID	GO:0000075
	UniProtAcc	Q9BTA9

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
51322	WAC	AEH-subject4	Human	Endometrium	AEH	1.24e-27	6.91e-01	-0.2657
51322	WAC	AEH-subject5	Human	Endometrium	AEH	1.30e-24	5.87e-01	-0.2953
51322	WAC	EEC-subject1	Human	Endometrium	EEC	3.33e-30	6.37e-01	-0.2682
51322	WAC	EEC-subject2	Human	Endometrium	EEC	7.80e-18	3.54e-01	-0.2607
51322	WAC	EEC-subject3	Human	Endometrium	EEC	7.57e-24	1.81e-01	-0.2525
51322	WAC	EEC-subject4	Human	Endometrium	EEC	2.94e-10	2.14e-01	-0.2571
51322	WAC	EEC-subject5	Human	Endometrium	EEC	3.80e-07	2.36e-01	-0.249
51322	WAC	GSM5276934	Human	Endometrium	EEC	1.22e-03	6.62e-02	-0.0913
51322	WAC	GSM6177620_NYU_UCEC1_lib1_lib1	Human	Endometrium	EEC	2.10e-37	6.18e-01	-0.1869
51322	WAC	GSM6177620_NYU_UCEC1_lib2_lib2	Human	Endometrium	EEC	4.77e-29	4.66e-01	-0.1875
51322	WAC	GSM6177620_NYU_UCEC1_lib3_lib3	Human	Endometrium	EEC	4.83e-35	4.99e-01	-0.1883
51322	WAC	GSM6177621_NYU_UCEC2_lib1_lib1	Human	Endometrium	EEC	1.81e-51	7.10e-01	-0.1934
51322	WAC	GSM6177622_NYU_UCEC3_lib1_lib1	Human	Endometrium	EEC	4.67e-44	2.94e-01	-0.1917
51322	WAC	GSM6177622_NYU_UCEC3_lib2_lib2	Human	Endometrium	EEC	7.04e-37	3.29e-01	-0.1916
51322	WAC	GSM6177623_NYU_UCEC3_Vis	Human	Endometrium	EEC	2.40e-05	1.16e-01	-0.1269
51322	WAC	LZE3D	Human	Esophagus	HGIN	4.08e-03	1.98e-01	0.0668
51322	WAC	LZE4T	Human	Esophagus	ESCC	4.45e-15	-4.22e-02	0.0811
51322	WAC	LZE8T	Human	Esophagus	ESCC	1.35e-04	5.64e-02	0.067
51322	WAC	LZE20T	Human	Esophagus	ESCC	4.34e-07	2.20e-02	0.0662
51322	WAC	LZE22T	Human	Esophagus	ESCC	4.93e-06	2.43e-01	0.068

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004217610	Cervix	CC	regulation of protein catabolic process	104/2311	391/18723	9.39e-15	9.36e-12	104
GO:190336210	Cervix	CC	regulation of cellular protein catabolic process	72/2311	255/18723	5.98e-12	2.10e-09	72
GO:001049810	Cervix	CC	proteasomal protein catabolic process	111/2311	490/18723	8.98e-11	1.58e-08	111
GO:000989610	Cervix	CC	positive regulation of catabolic process	109/2311	492/18723	5.26e-10	6.99e-08	109
GO:190305010	Cervix	CC	regulation of proteolysis involved in cellular protein catabolic process	60/2311	221/18723	1.82e-09	1.98e-07	60
GO:200005810	Cervix	CC	regulation of ubiquitin-dependent protein catabolic process	47/2311	164/18723	1.63e-08	1.25e-06	47
GO:004316110	Cervix	CC	proteasome-mediated ubiquitin-dependent protein catabolic process	91/2311	412/18723	1.65e-08	1.25e-06	91
GO:004586110	Cervix	CC	negative regulation of proteolysis	80/2311	351/18723	2.88e-08	1.98e-06	80
GO:003133110	Cervix	CC	positive regulation of cellular catabolic process	91/2311	427/18723	9.64e-08	5.25e-06	91
GO:003133010	Cervix	CC	negative regulation of cellular catabolic process	63/2311	262/18723	1.10e-07	5.68e-06	63
GO:00447725	Cervix	CC	mitotic cell cycle phase transition	89/2311	424/18723	2.70e-07	1.12e-05	89
GO:006113610	Cervix	CC	regulation of proteasomal protein catabolic process	48/2311	187/18723	4.63e-07	1.77e-05	48
GO:003243410	Cervix	CC	regulation of proteasomal ubiquitin-dependent protein catabolic process	38/2311	134/18723	4.99e-07	1.88e-05	38
GO:000989510	Cervix	CC	negative regulation of catabolic process	69/2311	320/18723	2.15e-06	6.55e-05	69
GO:20000453	Cervix	CC	regulation of G1/S transition of mitotic cell cycle	37/2311	142/18723	6.33e-06	1.53e-04	37
GO:19033639	Cervix	CC	negative regulation of cellular protein catabolic process	24/2311	75/18723	6.43e-06	1.55e-04	24
GO:00000824	Cervix	CC	G1/S transition of mitotic cell cycle	49/2311	214/18723	1.16e-05	2.48e-04	49
GO:19028062	Cervix	CC	regulation of cell cycle G1/S phase transition	41/2311	168/18723	1.18e-05	2.51e-04	41
GO:00073466	Cervix	CC	regulation of mitotic cell cycle	88/2311	457/18723	1.26e-05	2.60e-04	88
GO:19019903	Cervix	CC	regulation of mitotic cell cycle phase transition	63/2311	299/18723	1.27e-05	2.60e-04	63

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

WAC

SNV

Missense_Mutation

c.306C>G

p.His102Gln

p.H102Q

Q9BTA9

protein_coding

tolerated(0.13)

benign(0.063)

TCGA-A2-A3XT-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

WAC

SNV

Missense_Mutation

c.1142N>C

p.Val381Ala

p.V381A

Q9BTA9

protein_coding

deleterious(0.03)

possibly_damaging(0.503)

TCGA-A8-A06X-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WAC

SNV

Missense_Mutation

novel

c.1798N>A

p.Glu600Lys

p.E600K

Q9BTA9

protein_coding

tolerated(0.09)

probably_damaging(0.972)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WAC

SNV

Missense_Mutation

novel

c.16A>G

p.Arg6Gly

p.R6G

Q9BTA9

protein_coding

deleterious(0.04)

benign(0)

TCGA-AQ-A7U7-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Targeted Molecular therapy

rituximab

WAC

SNV

Missense_Mutation

rs200723559

c.1586N>G

p.Asn529Ser

p.N529S

Q9BTA9

protein_coding

tolerated(0.13)

possibly_damaging(0.584)

TCGA-BH-A0E0-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

docetaxel

WAC

SNV

Missense_Mutation

rs750794271

c.376N>C

p.Asp126His

p.D126H

Q9BTA9

protein_coding

deleterious(0.01)

probably_damaging(0.995)

TCGA-D8-A27G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WAC

SNV

Missense_Mutation

c.1887N>C

p.Leu629Phe

p.L629F

Q9BTA9

protein_coding

deleterious(0)

probably_damaging(0.991)

TCGA-E2-A10C-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

WAC

SNV

Missense_Mutation

c.1595C>A

p.Ser532Tyr

p.S532Y

Q9BTA9

protein_coding

tolerated(1)

possibly_damaging(0.598)

TCGA-GM-A2D9-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

WAC

insertion

Frame_Shift_Ins

novel

c.1537_1538insT

p.Arg513LeufsTer8

p.R513Lfs*8

Q9BTA9

protein_coding

TCGA-A2-A0EO-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

WAC

insertion

Frame_Shift_Ins

novel

c.1538_1539insAGGGAGAATTATTAATCATATCCCCTCACCCCACCAA

p.Ser514GlyfsTer19

p.S514Gfs*19

Q9BTA9

protein_coding

TCGA-A2-A0EO-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

Page: 1 2 3 4 5 6 7 8

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1